How Elacestrant Targets Breast Cancer Cells
Elacestrant (brand name Orserdu) treats ER-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women or adult men with ESR1 mutations. It binds selectively to the estrogen receptor alpha (ERα), a protein that drives cancer growth in these hormone-sensitive tumors. By competing with estrogen, elacestrant locks the receptor in an inactive conformation, blocks DNA binding, and recruits corepressors to suppress ER-dependent gene transcription that promotes tumor proliferation.[1][2]
This oral selective estrogen receptor degrader (SERD) induces ERα protein degradation, reducing receptor levels in cancer cells and halting estrogen signaling pathways. ESR1 mutations, which occur in about 40% of metastatic cases after prior endocrine therapy, make tumors resistant to standard treatments like tamoxifen or aromatase inhibitors; elacestrant overcomes this by directly degrading the mutated receptor.[3]
How Patients Take It and Expected Response
Patients take 345 mg orally once daily with food. In the phase 3 EMERALD trial, it extended progression-free survival to 3.8 months versus 1.9 months with standard endocrine therapy in ESR1-mutated patients, with confirmed objective response rates of 22%.[1][4] It shrinks tumors or slows growth in roughly one-fifth of resistant cases.
Who Qualifies and When Doctors Prescribe It
FDA approved in January 2023 for post-endocrine therapy progression, confirmed via FDA-approved ESR1 tests like Guardant360 CDx. It's not first-line; prior use of endocrine therapy plus CDK4/6 inhibitors is typical. Not for ER-negative or HER2-positive breast cancer.[2]
Common Side Effects and What Patients Experience
Fatigue (40%), nausea (35%), decreased appetite (25%), and vomiting affect most users, mostly mild. Serious risks include sinusitis, musculoskeletal pain, and QT prolongation; 3% discontinued due to adverse events. Liver function monitoring is required.[1][4]
How It Stacks Up Against Fulvestrant or Other SERDs
Unlike injectable fulvestrant (another SERD), elacestrant is oral with better bioavailability. In EMERALD, it outperformed physician's choice (aromatase inhibitors + fulvestrant) in ESR1-mutated subgroups. Emerging oral SERDs like camizestrant show similar PFS benefits in trials, but elacestrant is first approved.[3][5]
Patent Status and Availability Timeline
Menarini holds U.S. patents on elacestrant through 2037-2041 for composition and use claims; no generic challenges listed yet.[6] Exclusivity runs to 2028 under Hatch-Waxman.
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217358s000lbl.pdf
[2] NCCN Guidelines: https://www.nccn.org/guidelines
[3] NEJM EMERALD Trial: https://www.nejm.org/doi/full/10.1056/NEJMoa2203960
[4] Orserdu HCP Site: https://www.orserdu.com
[5] Lancet Oncology Review: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00396-5/fulltext
[6] DrugPatentWatch: https://www.drugpatentwatch.com/p/tradename/ORSERDU